Skip to main content
. 2017 Jun 27;61(7):e00363-17. doi: 10.1128/AAC.00363-17

TABLE 3.

De novo resistance selections with grazoprevir in the GT4a replicon

Grazoprevir concn (nM) Treatment (fold EC50) Mutations (% population)a
No drug 0 A61T (100), G90R (5)
1 1 A61T (100), G90R (5)
3 3 A61T (100), G90R (5), G162R (5)
10 10 A61T (70), G90R (5), D168V (30), D168G (30)
30 30 A61T (95), G90R (5), D168V (50), D168A (50)
a

Key amino acid substitutions deduced from population sequencing of resistant colonies and quantified based on peaks from the electropherogram are indicated.